Myeloma Trial, Recruiting NCT03016806 Sponsor: University of Rochester Condition: Myeloma
Back to Myeloma

Myeloma Trial, Recruiting

NCT03016806
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have a disease or condition that can be treated with a stem cell transplant, such as certain immune system disorders (for example, Severe Combined Immunodeficiency or Wiskott-Aldrich Syndrome), bone marrow failure conditions, metabolic diseases (such as Hurler's Syndrome), or severe aplastic anemia
  • You have a high-risk blood cancer such as certain types of leukemia (including AML, ALL, CML, or other rare forms) that did not respond well to standard treatment, came back after treatment, or has certain high-risk features (confirm specific cancer type and status with trial site)
  • You have a lymphoma (such as large cell, mantle cell, or Hodgkin lymphoma) that has come back or did not respond to treatment, and you are not able to have your own stem cells transplanted, or you have already had that type of transplant
  • You have multiple myeloma that has come back after a previous stem cell transplant using your own cells, or you are not eligible for that type of transplant
  • You have a solid tumour where a donor stem cell transplant has been shown to be effective for your specific situation (confirm with trial site)
  • Your heart is working well enough, with no serious heart rhythm problems or heart failure
  • Your lungs are functioning at least 50% of the expected level for a healthy person
  • Your kidneys are working adequately (confirm specific values with trial site)
  • Your liver is functioning within acceptable limits, with no serious liver problems (some exceptions may apply — confirm with trial site)
  • You are well enough to carry out most daily activities (a score of 70% or above on a standard health performance scale)
  • You have given your informed consent before starting any treatment related to the transplant
  • A suitable cord blood stem cell donation has been confirmed as available before starting treatment

Who may not be able to join:

  • A well-matched stem cell donor (related or unrelated) is already available and can donate within a timeframe that suits your medical needs
  • You have had a stem cell transplant using your own cells within the last 6 months
  • You are currently pregnant or breastfeeding
  • You currently have an infection that is not under control
  • You are HIV-positive or have tested positive for HIV

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 8 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Omar Aljitawi, MD, Professor - Department of Medicine, Hematology/Oncology (SMD)

Phone: 585-275-4099

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 June 2015
Est. completion
1 June 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Engraftment of ANC and Platelets

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov